Patient Support and Educational Materials
Patients' FAQs
Spartina® is a prescription medicine used for weight management, improving blood sugar control in adults with type 2 diabetes and treatment of obstructive sleep apnea. It works together with a reduced-calorie diet and increased physical activity.
Spartina® is given as a once-weekly injection under the skin, in the abdomen, thigh, or upper arm. Always follow your healthcare provider’s instructions for use.
In clinical studies, participants treated with tirzepatide experienced a percent reduction in fat mass approximately three times greater than the reduction in lean mass which resulted in an overall improvement in body composition.
If you miss a dose, take it as soon as you remember within 4 days (96 hours). If more than 4 days have passed, skip the missed dose and take your next dose on your regular day. Do not take two doses at once.
The most common side effects are nausea, vomiting, diarrhea, constipation, and stomach pain. These usually improve over time. Always talk to your doctor if symptoms are severe or persistent.
Spartina® may cause worsening of diabetic retinopathy, pancreatitis, gallbladder disease, or low blood sugar (especially if taken with insulin or sulfonylureas). Speak with your doctor if you notice neck lumps, severe abdominal pain, or vision changes.
No. Spartina should not be used during pregnancy. If you are planning to become pregnant, speak with your doctor before starting treatment.
Do not use Spartina® with other medicines that contain tirzepatide or GLP-1 receptor agonists. Your doctor will review your other medications before starting Spartina.
Keep Spartina® physiojects or pens in the refrigerator at 2°C to 8°C. Do not freeze. Keep away from heat and direct light.
Call your doctor immediately if you notice severe stomach pain, symptoms of low blood sugar (such as sweating, shaking, or dizziness), signs of an allergic reaction (such as swelling or difficulty breathing), or vision changes.
People with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or those with a history of serious allergic reaction to tirzepatide, should not use Spartina.